---
figid: PMC2906469__1476-4598-9-144-4
figtitle: Targeting GSK3B pathway may be highly beneficial for curing oral cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC2906469
filename: 1476-4598-9-144-4.jpg
figlink: /pmc/articles/PMC2906469/figure/F4/
number: F4
caption: Targeting GSK3β pathway may be highly beneficial for curing oral cancer.
  Inhibition of GSK3β activity by the activation of several oncogenic pathways in
  cancer as discussed in the text. Activation of these pathways by several oral cancer
  etiological factors is interesting and fuel for inactivating GSK3β by targeting
  its inactivating pathways to promote oral cancer. Two major therapeutic strategies
  may be adopted to keep GSK3β active. First and the most important will be to (---)
  prevent the inactivation of GSK3β, by targeting its upstream inhibitory kinases,
  so that they will remain unassociated. Second will be to (---) reconstitute the
  active GSK3β (Ala9GSK3β by gene therapy) to affected oral cancer sites.
papertitle: 'Glycogen synthase kinase 3 beta: can it be a target for oral cancer.'
reftext: Rajakishore Mishra. Mol Cancer. 2010;9:144-144.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9622662
figid_alias: PMC2906469__F4
figtype: Figure
redirect_from: /figures/PMC2906469__F4
ndex: c8f28db5-ded9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2906469__1476-4598-9-144-4.html
  '@type': Dataset
  description: Targeting GSK3β pathway may be highly beneficial for curing oral cancer.
    Inhibition of GSK3β activity by the activation of several oncogenic pathways in
    cancer as discussed in the text. Activation of these pathways by several oral
    cancer etiological factors is interesting and fuel for inactivating GSK3β by targeting
    its inactivating pathways to promote oral cancer. Two major therapeutic strategies
    may be adopted to keep GSK3β active. First and the most important will be to (---)
    prevent the inactivation of GSK3β, by targeting its upstream inhibitory kinases,
    so that they will remain unassociated. Second will be to (---) reconstitute the
    active GSK3β (Ala9GSK3β by gene therapy) to affected oral cancer sites.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Oamb
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - rs
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - ra
  - Mtor
  - Tor
  - ac
  - Raf
  - MKP-4
  - p38b
  - rl
  - Axn
  - Apc
  - Apc2
  - Fs(3)Apc
  - Amph
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Akt
  - S6k
  - arm
  - CG1673
  - ATPsynbeta
  - Atpalpha
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Myc
  - cyc
  - CycE
  - Cyt-c-d
  - Cyt-c-p
  - cype
  - Dif
  - dl
  - Rel
  - sna
  - AP-1gamma
  - Jra
  - kay
  - p53
  - betaTub60D
  - hth
  - Orai
  - NUTM1
  - EGFR
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - MTOR
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AXIN1
  - AXIN2
  - APC
  - PROC
  - APRT
  - MFAP1
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - AKT1
  - PTK2B
  - RPS6KB1
  - RPS6KB2
  - ATP8A2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - MYC
  - CYCS
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - SNAI1
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - TP53
  - TP63
  - TP73
  - ITK
  - SLC22A3
  - Nicotine
  - Cancer
  - Lung cancer
---
